DCs combined with antigens from a tumor or virus can produce major histocompatibility complex (MHC) class I and class II peptide epitopes to CD8 and CD4 T lymphocytes, leading to a series of immune reactions in response to the antigens. This evidence concerns the gene CD8A and neoplasm.